Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review outlines the histological structures of the skin, highlighting species and regional differences in dermal absorption and obstacles encountered in toxicological assessments due to epidermal thickness variability, contact dermatitis reactions, and stem cell vulnerabilities.

This study found that vibration anesthesia significantly reduced pain during botulinum toxin injections for masseter reduction without affecting the injection's diffusion or causing adverse effects, and high patient satisfaction was also reported.

This study suggests that a mild intramuscular dose of botulinum toxin improved spermatogenesis and sperm parameters in ageing mice.

This review reports that botulinum toxin is used in dermatology not only for treating rhytides but also for conditions like rosacea, hyperhidrosis, and menopause-related flushing, although its full safety and efficacy profile requires more research.

This review discusses the pathogenesis and treatment of hidradenitis suppurativa and examines botulinum toxin type A as a potential therapeutic option, but reports no new clinical results.

This case report describes an inflammatory skin reaction linked to kava kava ingestion, with the patient's condition resolving after treatment with oral prednisone and topical hydrocortisone.

This study concluded that there was clear evidence of carcinogenic activity of C.I. Acid Orange 3 in female F344/N rats but not in male rats or B6C3F1 mice of either sex.

This study highlights the growing use of botulinum toxin in both medical and cosmetic fields, showing its benefits and risks. Proper administration is crucial to avoid severe side effects like muscle weakness and respiratory issues, emphasizing the need for enhanced safety measures and regulations.

This study reviews current trends and the state of research on botulinum toxin in dermatology, aiming to help researchers identify key areas and explore new research directions.

In this study, complete recovery from folliculitis dissecans was observed after intradermal botulinum toxin A injections, with the effect attributed to the host response rather than direct bacterial action.

This article reviews skin toxicity classifications and management in patients undergoing molecularly targeted therapy, noting significant dermatotropic side effects associated with Epidermal Growth Factor Receptor Inhibitors.

This case report suggests that intradermal botulinum toxin type A may alleviate pruritus and reduce papules in Fox-Fordyce disease, improving quality of life without serious adverse effects for at least six months.

This systematic review of five studies found that intradermal and intramuscular botulinum toxin injections showed promising hair growth outcomes for men with androgenic alopecia, but emphasizes caution due to a lack of control groups and small sample sizes.

The researchers reported that intralesional botulinum toxin A effectively alleviated pain associated with cutaneous leiomyomas in a patient with hereditary leiomyomatosis and renal cell cancer syndrome, with repeated treatments every three months maintaining pain relief over 1.5 years.

This study found that supplementing arsenic-fed Black Bengal kids with vitamin E, alone or combined with yeast culture, partially ameliorated growth and reduced arsenic load in faeces, urine, and hair.

This review discusses the potential mechanisms by which intradermal botulinum toxin may affect androgenetic alopecia but notes that high-evidence clinical trials have yet to show conclusive results.

This review found that adding immune checkpoint inhibitors to cancer treatment regimens likely increases the incidence of specific drug-related skin toxicities in adult Asian patients, highlighting the need for careful monitoring and management strategies.

This study found that isorhamnetin, a compound from the Rampai plant, showed a lower affinity energy in molecular docking tests compared to Minoxidil, indicating potential as an androgen receptor antagonist for alopecia therapy in silico, with favorable pharmacokinetic characteristics in ADME-Tox predictions.

This narrative review highlights that endurance, skill-oriented athletes, and physique-oriented competitors such as bodybuilders face accelerated degradation of fillers and botulinum neurotoxin due to elevated basal metabolic rates and other factors, and raised concerns about psychological conditions like body dysmorphic disorder in these populations.

This review examines current literature on botulinum toxin type A for androgenetic alopecia, reporting an association with increased hair growth and improved hair density, though further research is needed.

In this retrospective analysis, patients with trichodynia who were unresponsive to standard treatments showed significant symptom improvement after receiving intradermal botulinum toxin type A, with nearly all patients benefiting, particularly those with scarring alopecia.

This study reported that dermatological adverse events are common in patients treated with amivantamab for non-small cell lung cancer, often impacting quality of life and requiring treatment modifications.

This study assessed mice's hematology and serum enzymes under sodium arsenite toxicity and observed that Aegle marmelos fruit extract reduced liver and kidney damage, mitigating the toxin's effects by maintaining normal enzyme levels when both were administered together.

This study found that glycyrrhizic acid may reduce the cutaneous toxicity caused by Osimertinib in mice, suggesting its potential as an adjunct treatment in clinical settings.

This paper proposes a novel theory that certain symptoms of Post-Finasteride Syndrome may be caused by an overgrowth of hydrogen sulphide-producing bacteria in the small intestine, which acts as a mitochondrial toxin, with implications for treatment targeting the gut microbiome.

This theoretical paper proposes that a subset of Post-Finasteride Syndrome cases may be driven by a gut-derived toxic process involving hydrogen sulphide-producing bacteria, suggesting that the small intestinal microbiome could be a potential target for treating this condition.

This narrative review concluded that facial aging involves complex anatomical changes that require multimodal rejuvenation approaches, integrating fillers, collagen stimulators, botulinum toxin, and energy-based devices for effective results, while emphasizing the need for scientific evidence and patient safety in aesthetic treatments.

In this randomized controlled trial, both Botulinum Toxin-A and Triamcinolone Acetonide showed substantial effectiveness in treating patchy Alopecia Areata, but Botulinum Toxin-A avoided complications while Triamcinolone led to skin atrophy in 16.7% of patients.

In this systematic review and meta‐analysis, botulinum toxin monotherapy was found to significantly increase hair density in patients with androgenetic alopecia, with optimal effects observed using a 100-unit dose every six months. These findings suggest potential efficacy but should be confirmed in larger, placebo-controlled trials.